Department of Health Promotion Sciences Maternal and Infantile Care, Internal Medicine and Medical Specialities "Giuseppe D'Alessandro", University of Palermo, Via del Vespro 133, 90127 Palermo, Italy.
Dipartimento di Biomedicina, Neuroscienze e Diagnostica Avanzata (BiND), Sezione di Audiologia, Università Degli Studi di Palermo, Via del Vespro 129, 90127 Palermo, Italy.
Int J Environ Res Public Health. 2021 Apr 30;18(9):4787. doi: 10.3390/ijerph18094787.
Vertigo is not itself a disease, but rather a symptom of various syndromes and disorders that jeopardize balance function, which is essential for daily activities. It is an abnormal sensation of motion that usually occurs in the absence of motion, or when a motion is sensed inaccurately. Due to the complexity of the etiopathogenesis of vertigo, many pharmacological treatments have been tested for efficacy on vertigo. Among these drugs, cinnarizine, usually given together with dimenhydrinate, appears to be the first-line pharmacotherapy for the management of vertigo and inner ear disorders. Based on these considerations, the present non-interventional study aimed to investigate the clinical efficacy and tolerability of a fixed combination of cinnarizine (20 mg) and dimenhydrinate (40 mg) in patients suffering from vertigo-related symptoms. To this end, we enrolled 120 adults-70 males, and 50 females-with an average age of 64 years. Before beginning pharmacological treatment, all patients were screened for the intensity of vertigo, dizziness, and concomitant symptoms through the Visual Scale of Dizziness Disorders and Dizziness Handicap Inventory scales. At the end of the anamnestic evaluation, patients received the fixed-dose combination of cinnarizine (20 mg) plus dimenhydrinate (40 mg) 3 times daily, for 60 days. The results of this study provide further insight regarding the efficacy of the fixed combination when used to reduce symptoms of vestibular vertigo of central and/or peripheral origin, after both the 15- and 60-day therapies. Independent of the type of vertigo, the fixed combination was able to reduce dizziness- and vertigo-associated symptoms in more than 75% of all patients treated, starting from 15 days of therapy, and improving 60 days after starting the therapy. Interestingly, we also found differences between male and female patients in the framework of the pharmacological effects of therapy. This study provides further details concerning the therapeutic efficacy of the fixed combination of cinnarizine and dimenhydrinate, and also focuses attention on the possibility that these drugs could act in a gender-specific manner, paving the way for further research.
眩晕本身不是一种疾病,而是各种威胁平衡功能的综合征和疾病的症状,平衡功能对日常活动至关重要。它是一种异常的运动感觉,通常在没有运动或感觉到不准确的运动时发生。由于眩晕的病因发病机制复杂,许多药物治疗已被测试用于眩晕的疗效。在这些药物中,桂利嗪通常与茶苯海明一起使用,似乎是治疗眩晕和内耳疾病的一线药物治疗。基于这些考虑,本非介入性研究旨在调查桂利嗪(20 毫克)和茶苯海明(40 毫克)固定组合在患有与眩晕相关症状的患者中的临床疗效和耐受性。为此,我们招募了 120 名成年人-70 名男性和 50 名女性-平均年龄为 64 岁。在开始药物治疗之前,所有患者都通过眩晕障碍视觉量表和眩晕障碍残疾量表筛查了眩晕、头晕和伴随症状的强度。在病史评估结束时,患者每天接受 3 次桂利嗪(20 毫克)加茶苯海明(40 毫克)的固定剂量联合治疗,为期 60 天。这项研究的结果提供了更多关于固定组合在减少中枢和/或外周起源的前庭眩晕症状方面的疗效的见解,无论是在 15 天还是 60 天的治疗后。独立于眩晕的类型,固定组合能够在开始治疗后 15 天开始,在超过 75%的治疗患者中减轻与头晕和眩晕相关的症状,并在开始治疗 60 天后改善。有趣的是,我们还在治疗的药理学作用框架内发现了男性和女性患者之间的差异。这项研究提供了关于桂利嗪和茶苯海明固定组合的治疗疗效的更多细节,并引起了对这些药物可能以性别特异性方式发挥作用的关注,为进一步研究铺平了道路。